Accueil
Vaccine and vaccination PDF Imprimer

Diphtheria is preventable through active immunization. Effective control of the disease can be ensured through high population immunity by providing three doses of diphtheria-containing vaccine to all children below one year of age. The first dose of diphtheria-containing vaccine is given to children at age 6 weeks and then at least four weeks apart for the second and third dose of the vaccine. 

Diphtheria vaccine is a toxoid that is available in different combinations with other vaccines. Diphtheria vaccine is safe, effective and well tolerated.

 
Smokeless tobacco use PDF Imprimer

Smokeless tobacco

In many parts of the world, including in the WHO Eastern Mediterranean Region, people use smokeless tobacco. The tobacco is usually chopped up and moistened, and is used by chewing it or holding it in the mouth between the gum and the cheek.

Chewing tobacco is sometimes mixed with other substances including herbs, spices, areca nut, betel leaf and slaked lime. Different forms include paan, naswar, chalia/supari and gutkha. Gutkha is a commercially-manufactured smokeless chewing tobacco that is a sweetened and flavoured dry mixture which is increasingly popular among young people and women in some countries. 

Health risks of smokeless tobacco use                                    

Smokeless tobacco use is highly addictive and damaging to health. The nicotine in smokeless tobacco is more easily absorbed than by smoking cigarettes enhancing its addictiveness. Smokeless tobacco contains many cancer-causing toxins and its use increases the risk of cancers of the head, neck, throat, oesophagus and oral cavity (including cancer of the mouth, tongue, lip and gums) as well as various dental diseases.

In Pakistan, where rates of smokeless tobacco use are high (and higher than cigarette use), oral cancer rates are among the highest in the world, and are significantly higher than other countries of the Region. Oral cancer is the second leading cancer there after breast cancer. Smokeless tobacco users have much higher rates of oral cancer than non-users.

Gutkha has been strongly implicated in an increase in oral submucous fibrosis, a very malignant and debilitating condition with no cure. This rise is being seen especially among young people, even after a short period of use. 

Increasing use of smokeless tobacco

Smokeless tobacco use in the Region is increasing rapidly, especially among young people and women. The Region has some of the highest rates in the world with overall rates of use of tobacco products other than cigarettes (including smokeless tobacco) of 14% among boys age 13–15 (compared to 7% cigarette use) and 9% among girls age 13–15 (compared to 2% cigarette use). Rates are even higher in some countries of the Region. In many countries, more women and young people use other tobacco products than smoke cigarettes.

Underlying this increase is the misperception that use of tobacco products such as smokeless tobacco is less harmful to health than smoking cigarettes. Smokeless tobacco is not a safe alternative to cigarettes. However, the health dangers of smokeless tobacco use are little understood by users.

Marketing smokeless tobacco              

Smokeless tobacco is being increasingly marketed by the tobacco industry. This includes marketing to cigarette smokers as an alternative in situations in which smoking is not allowed. It is also marketed to young people to promote initiation of tobacco use. Smokeless tobacco is often easier for young people to obtain than cigarettes and is easier to use without drawing attention.

Smokeless tobacco has not had the same amount of regulation as cigarettes. In most countries, the smokeless tobacco sold does not carry health warnings on its packaging. This reinforces the perception that smokeless tobacco use is relatively safe compared to cigarettes.

Best practices and the way forward

Smokeless tobacco use should be subject to the same regulation as cigarettes and other tobacco products. This includes application of Article 9 of the WHO Framework Convention on Tobacco Control on the regulation of the contents and emissions of tobacco products, Article 10 on the regulation of tobacco product disclosures and Article 11 on packaging and labelling of tobacco products.

Smokeless tobacco use should be included in tobacco control efforts. This includes:

prohibition of misleading labelling and claims of reduced harm and safety

having health warnings on smokeless tobacco packaging           

education of the public and health professionals about the health risks of smokeless tobacco use

cessation interventions for smokeless tobacco users. 

 
Vaccine and vaccination PDF Imprimer

Currently, four inactivated vaccines against hepatitis A virus are available. All four vaccines are safe and effective, with long-lasting protection. None of the vaccines are licensed for children aged under one year.

Hepatitis A vaccine can be given to anyone who wants to be immunized against the condition. However, people who travel to parts of the world where sanitation is not very good should be immunized.

Hepatitis B vaccine is available as monovalent formulations or in fixed combination with other vaccines, including diphtheria–tetanus–pertussis, Haemophilus influenzae type b, hepatitis A and inactivated polio vaccine. The immune responses and safety of these combinations of vaccines are comparable to those observed when the vaccines are administered separately.

Hepatitis B vaccination is recommended for all infants, older children and adolescents who were not vaccinated previously, and adults at risk for hepatitis B virus infection. The first dose of hepatitis B vaccine should be given within the first 24 hours after birth even in low-endemicity countries. The birth dose should be followed by two or three doses with a minimum interval of four weeks.

Hepatitis B vaccine has been introduced as part of routine immunization in all countries of the WHO Eastern Mediterranean Region, except Somalia and South Sudan. It is expected to be introduced in Somalia in early 2013. Fourteen countries in the Region are implementing the birth dose of hepatitis B vaccine.

 
Vaccine and vaccination PDF Imprimer

Vaccinating children against Hib has been very successful in significantly decreasing rates of Hib disease and almost eliminating the disease in countries that introduced the vaccine with high vaccination coverage. Healthy recipients may be susceptible to Hib disease for one or two weeks until antibodies are developed. 

Hib vaccine is currently available as single or in different combinations. The first dose of Hib containing vaccine is recommended to children aged 6 weeks or more and at least four weeks interval between the second and third dose of the vaccine. 

Some older children and adults with special conditions are at an increased risk for infection with Hib and should be vaccinated with one dose of the vaccine if they were not vaccinated in childhood. These conditions include sickle cell disease, removal of the spleen, bone marrow transplant, cancer treatment with drugs that weaken the immune system, and human immunodeficiency virus (HIV).

 
Vaccine and vaccination PDF Imprimer

Please enter your text here

 


Page 43 sur 93